EUCTR2007-000192-42-NL进行中（未招募）不适用
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment with Two Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by a Treatment with BOTOX® in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity
Allergan Ltd0 个研究点目标入组 260 人开始时间: 2007年5月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1] Patient is male or female, aged 18 to 80 years old
- •[2] Patient weighs = 50 kg (110 lb)
- •[3] Written informed consent has been obtained
- •[4] Written Authorization for Use and Release of Health and Research Study Information (US sites only) has been obtained
- •[5] Written Data Protection Consent (European sites only) has been obtained
- •[6] Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable
- •[7] Patient has urinary incontinence as a result of neurogenic detrusor overactivity for a period of at least 3 months prior to screening as a result of spinal cord injury or multiple sclerosis, determined by documented patient history. In addition
- •[7a] Spinal cord injury patients must have a stable neurological injury level at T1 or below (cervical injuries are excluded) occurring = 6 months prior to screening;
- •[7b] Multiple sclerosis patients must be clinically stable in the investigator’s opinion, for = 3 months prior to screening and have an Expanded Disability Status Scale (EDSS) score = 6.5.
- •[8] Patient has detrusor overactivity (defined as a phasic rise in bladder pressure during the filling phase determined by urodynamics) demonstrated during the screening period or Day 1 (prior to randomization)
- •[9] Patient is able to complete study requirements including electronic bladder diary completion and attend all study visits (telephone and clinic), in the opinion of the investigator
- •[10] Patient has not been adequately managed with one or more anticholinergics for their urinary incontinence, in the opinion of the investigator. Not adequately managed is defined as an inadequate response or intolerable side effects after at least one month of anticholinergic therapy on an optimized dose
- •[11] For patients taking anticholinergic medication for their neurogenic overactive bladder, dose is stable and patient is willing to maintain same dosing during study participation
- •[12] Patient has a negative pregnancy result if female and of childbearing potential
- •The following criteria are also required for entry into the study at Randomization/Day 1:
- •[13] Patient experiences = 14 episodes of urinary incontinence per week with no more than 2 incontinent-free days, determined by completion of patient bladder diary during the screening period
- •[14] Patient currently uses or is willing to use clean intermittent catheterization (CIC) to empty the bladder (indwelling catheter is not permitted). Patients currently on CIC should be willing to maintain an established CIC frequency throughout the study. Caregiver may perform CIC
- •[15] Patients with a negative urine culture result must take an antibiotic medication for 3 days immediately prior to Randomization/Day 1 and agree to continue antibiotic medication for at least 3 days following treatment. Patients with a positive urine culture result indicating urinary tract infection (UTI), must take an antibiotic to which the identified organism is sensitive for at least 5 days immediately prior to Randomization/Day 1 and continue for 3 days following the procedure (or longer as needed) and patient is asymptomatic for UTI on day of treatment. A UTI is defined as either a positive urine culture result with a bacteriuria count of > 10^5 CFU/mL conjoint with a leukocyturia > 5/hpf at screening or a positive urine culture that, in the investigator’s opinion, requires antibiotic therapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age
排除标准
- •[1] Patient has history or evidence of any pelvic or urological abnormalities including but not limited to the following:
- •[1a] elevated serum creatinine > 2 times the upper limit of normal (reference range)
- •[1b] history of or current hematuria,
- •[1ba] if the hematuria is determined to be due to a pathologic condition or
- •[1bb] is uninvestigated
- •[1c] interstitial cystitis in the opinion of the investigator
- •[1d] bladder stones within 6 months of screening
- •[1e] surgery or bladder disease other than detrusor overactivity that may impact bladder function with the exception of surgeries for bladder stones (> 6 months) and stress incontinence, uterine prolapse, rectocele, or cystocele (>1 year) from screening
- •[2] Patient has had previous or current botulinum toxin therapy of any serotype for any urological condition or, treatment within 3 months of Randomization/Day 1 for any other condition or use.
- •[3] Patient has been immunized for any botulinum toxin serotype.
- •[4] Patient discontinued anticholinergic medication for overactive bladder < 21 days prior to Randomization/Day 1.
- •[5] Patient has a history or current diagnosis of bladder cancer or has urine cytology results which may indicate bladder cancer not ruled out by investigator at Randomization/Day 1. Suspicious urine cytology abnormalities require the investigator’s assessment to ensure that the findings are not indicative of malignancy.
- •[6] Patient is male with previous or current diagnosis of prostate cancer. Patients with a PSA level greater than 4.0 ng/mL will require a biopsy to rule out prostate cancer, unless a prostatic biopsy has been performed on the patient within the past 12 months.
- •[7] Patient has a detrusor compliance below 20 mL/cm H2O by urodynamic evaluation performed during the screening period through Day 1 (prior to randomization).
- •[8] Patient has 24 hour total volume voided > 3000 mL of urine determined by completion of patient bladder diary collected over one consecutive 24 hour period during the 7 day diary collection period prior to Randomization/Day1.
- •[9] Patient has a post void residual volume above 150 mL for patients who micturate or have a mixed catheterization/micturition pattern.
- •[10] Patient has an active genital infection, other than genital warts, either concurrently or within 4 weeks prior to screening.
- •[11] Patient uses any anti-platelet or anticoagulant therapy or is using medications with anticoagulative effects within 3 days prior to treatment. Some medications may need to be withheld for > 3 days per clinical judgment of the investigator.
- •[12] Patient has hemophilia or other clotting factor deficiencies or disorders that cause bleeding diatheses.
- •[13] Patient has had concurrent treatment or treatment within 6 months of Randomization/Day 1 with capsaicin or resiniferatoxin.
- •[14] Patient is currently using or plans to use an implanted or non-implantable electrostimulation/neuromodulation device for treatment of overactive bladder.
- •[15] Patient has a known allergy or sensitivity to any components of the study medication, anesthetics or antibiotics or any other products associated with the treatment and general study procedures.
- •[16] Patient has any medical condition that may put the patient at increased risk with exposure to BOTOX® including diagnosed myasthenia gravis, Eaton-Lambert syndrome or amyotrophic lateral sclerosis.
- •[17] Patient is female and pregnant, nursing or planning a pregnancy during the study, or of childbearing potential and
研究者
相似试验
进行中（未招募）
1 期
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-ResponseStudy to Evaluate the Safety and Efficacy of a Single Treatment of BOTOX®(Botulinum Toxin Type A) Purified Neurotoxin Complex Injected into the Prostatefor the Treatment of Lower Urinary Tract Symptoms in Patients due to BenignProstatic HyperplasiaPatients with lower urinary tract symptoms due to Benign Prostatic HyperplasiaMedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2005-004281-17-CZAllergan Inc.350
进行中（未招募）
不适用
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by a Treatment with BOTOX® as Applicable in Patients with Idiopathic Overactive Bladder with Urinary IncontinencePatients with symptoms of idiopathic overactive bladder (frequency and urgency) and urinary incontinence, whose symptoms have not been adequately managed with anticholinergic therapyMedDRA version: 12.0Level: LLTClassification code 10059617Term: Overactive bladderEUCTR2009-013088-20-NLAllergan Ltd534
未知
3 期
A Multicenter, Double-Blind, Randomized, Placebo-Controlled PhaseIII Study to Evaluate the Efficacy and Safety of OVF in Opioid tolerant Patients With Cancer and Breakthrough Pain.JPRN-jRCT2080221194Taiho Pharmaceutical Co., Ltd.
进行中（未招募）
不适用
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate theSafety and Antiretroviral Activity of MK-0518 in Combination With an OptimizedBackground Therapy (OBT), Versus Optimized Background Therapy Alone, in HIVInfected Patients With Documented Resistance to at Least 1 Drug in Each of the 3Classes of Licensed Oral Antiretroviral Therapies - Safety, PK, and Efficacy of MK-0518 plus OBT vs OBT Alone in HIV+nspecified human immuno-deficiency virus [HIV] diseaseMedDRA version: 7.0Level: LLTClassification code 10020162EUCTR2005-005127-34-PTMerck Sharp & Dohme, Lda.366
进行中（未招募）
不适用
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-ResponseStudy to Evaluate the Safety and Efficacy of a Single Treatment of BOTOX®(Botulinum Toxin Type A) Purified Neurotoxin Complex Injected into the Prostatefor the Treatment of Lower Urinary Tract Symptoms in Patients due to BenignProstatic HyperplasiaPatients with lower urinary tract symptoms due to Benign Prostatic HyperplasiaMedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2005-004281-17-ATAllergan Inc.350